WANY
HELP

Wealthspire Advisors (New York)’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Wealthspire Advisors (New York)’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-253
Closed -$1.49K – 1467
2025
Q3 		$1.49K Buy
+253
New +$1.79K ﹤0.01% 2677

Other funds holding HELP

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Wealthspire Advisors (New York)'s HELP Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Helus Pharma Inc. Common Stock (HELP) in Q4 2025, closing a stake of 253 shares — an estimated $1.49K sold.

Wealthspire Advisors (New York) first reported a position in HELP in Q3 2025 and held it in 1 quarter. The position peaked at $1.49K in Q3 2025. 80 funds tracked by Wall St. Rank hold HELP as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Helus Pharma Inc. Common Stock position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 253 Helus Pharma Inc. Common Stock shares in Q4 2025, an estimated $1.49K.
  • Wealthspire Advisors (New York) first reported a position in Helus Pharma Inc. Common Stock in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Helus Pharma Inc. Common Stock position peaked at $1.49K in Q3 2025.
  • 80 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.